Additionally, tumor cells can develop resistance to HSP inhibitors by compensatory upregulation of other chaperones or activating alternative survival pathways.[41] This limits the long-term effectiveness of single-agent HSP inhibitors. Here, HSP90B2P is linked to neoplasm.